REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (clinicaltrials.gov) - Apr 16, 2024 - P2/3 | N=600 | Recruiting | Sponsor: Sutro Biopharma, Inc. | Phase classification: P2 ➔ P2/3 | N=140 ➔ 600
Enrollment change • Phase classification • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • FOLR1
|